Smart Publications

Clarifying the Complex World of Nutrition Science

  • Email this article
  • Print this article
  • A
  • A
  • A

Policosanol: Start Improving Your Cholesterol Today

Proven safe!

Unlike statins, which become increasingly toxic with higher doses, Policosanol achieves its maximum effect at very low doses and taking more is neither more effective nor more toxic. In fact, Policosanol has undergone unusually extensive testing for a dietary supplement to prove its safety. Animal toxicity studies doses up to 1500 times the normal human dose (on the basis of body weight) have shown no negative effects on carcinogenesis,3839 reproduction, growth, and development,4041 including a study on three generations of rats.42 

In studies where it has been given to animals (rats and dogs) in megadoses, no drug-related toxicity was shown, and there was no negative effect on the animals (including body weight, food consumption and blood biochemistry) when compared with the control group.434445

Prevention is the best cure

Abnormal cholesterol levels are one of the causes of atherosclerosis, which diminishes the supply of blood to the heart and eventually leads to heart attacks. Atherosclerosis affects blood vessels throughout your body and also contributes to angina (chest pain), intermittent claudication (pain caused by blockage of arteries in the legs), and stroke.

Reduce cholesterol with Policosanol and see the amazing results!

Now it's easier than ever to control your blood cholesterol with Policosanol!

We've spent a lot of time and effort searching for the very best product available and are proud to recommend it. You won't find this high-quality product on the shelf of your natural foods store. And you won't find another product that will have the amazing success rate as Policosanol for normalizing your blood lipids and lowering your risk of heart disease, without ANY side effects!  

A Cholesterol Primer

Total Cholesterol - HDL Cholesterol - LDL Cholesterol - Triglycerides

Cholesterol is carried in blood in the form of substances called lipoproteins. Cardiovascular risk can be assessed by measuring total blood cholesterol, as well as the proportions of the different types of lipoproteins.

  1. Total cholesterol is the most common measure of blood cholesterol and the only number many people get from their doctor. Cholesterol is measured in milligrams per deciliter (mg/dL) of blood. A total cholesterol reading less than 200 mg/dL means a lower risk of heart disease, which everyone should try to attain. (Although cholesterol is not the only marker for heart disease risk. See "How much do you really know about heart disease?" 200-239 is borderline high cholesterol, and 240 and over is high cholesterol.
Lipoproteins
  1. HDL cholesterol, the "good" cholesterol, helps carry cholesterol out of the body, including cholesterol deposited inside blood vessels, where it may block the flow of blood. If there is too much cholesterol for the HDLs to pick up, or an inadequate supply of HDLs, cholesterol may aggregate into plaque groups that block arteries. Those blockages are the main cause of heart attacks. Remember that higher is healthier. A reading of less than 40 is low, at or greater than 60 is high, and having a level of 60 or greater is considered a "negative" risk factor that can offset another risk factor.
     
  2. LDL cholesterol, the "bad" cholesterol, hauls cholesterol from the liver to all cells in the body. Remember that lower is healthier. A reading of less than 100 is optimal; 100-129 is near or above optimal; 130-159, borderline high; 160-189, high; 190 or greater is very high.
Rule of thumb: You want to raise your HDL and lower your LDL.
  1. Triglycerides make up most of the body's fat, and are the storehouse for energy. Edible oils from seeds, egg yolk and animal fats also are composed mainly of triglycerides. They may not be as corrosive as LDL, but excess triglycerides exacerbate heart disease potential when they oxidize and damage artery linings or induce blood cells to clump. A reading of under 100 is optimal; under 200 is normal; 200-400 is borderline high; over 400 is high.

    When high triglycerides and low HDL occur together, risk of cardiovascular disease, high blood pressure, heart and kidney failure and other degenerative diseases increase.

    In fact, another up-and-coming index of heart disease risk is your triglyceride-to-HDL ratio. A ratio of less than 2 is considered good.

    The best ways to lower your triglyceride levels are to reduce your intake of carbohydrates, especially sugar and starch foods; and take a high-quality fish oil product.

Page 3 of 3 pages  < 1 2 3

Editor's Note:

The natural health solutions described in this article are available through many on-line retailers including those listed below. By clicking these links you help support the important alternative health research we provide.

Visit www.amazon.com – a great way to find competitive deals on supplements offered by many different manufacturers.

Visit www.hfn-usa.com – when commitment to quality and freshness is important, this factory direct solution is preferred by many of our readers.

This article is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a physician before embarking on a dietary supplement program.

References

  1. Antti Jula, MD, PhD; Jukka Marniemi, PhD; Risto Huupponen, MD, PhD; Arja Virtanen, MSc; Merja Rastas, MSc; Tapani Rönnemaa, MD, PhD "Effects of Diet and Simvastatin on Serum Lipids, Insulin, and Antioxidants in Hypercholesterolemic Men." JAMA Feb. 6, 2002, Vol. 287 #5, pp. 598-605. No. 5. 

    Abstract ↑

  2. http://abcnews.go.com/sections/living/DailyNews/zetia021029.html 

    ↑

  3. http://www.baycol-law.com/pdf/20020118_MSNBC_cholesterol_drug.pdf 

    ↑

  4. Menendez R, Amor AM, Rodeiro I, et al, Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res2001 Jan-Feb;32(1):8-12. 

    Abstract ↑

  5. Menendez R, Amor AM, Gonzalez RM, Fraga V, Mas R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29(2):253-7 

    Abstract ↑

  6. Menendez R, Fernandez SI, Del Rio A, et al, Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27(3-4):199-203

    Abstract ↑

  7. Janikula M, Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002 Jun;7(3):203-17 

    Abstract ↑

  8. Arruzazabala ML, Noa M, Menendez R, et al, Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz J Med Biol Res 2000 Jul;33(7):835-40 

    Abstract ↑

  9. Rodriguez-Echenique C, Mesa R, Mas R, Noa M, et al, Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 1994 Jun;32(6):565-75 

    Abstract ↑

  10. Mirkin A, Mas R, Martinto M, Boccanera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yanez M, Irico G, McCook B, Farre A. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001;21(1):31-41. 

    Abstract ↑

  11. Janikula M. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002 Jun;7(3):203-17. 

    Abstract ↑

  12. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65. 

    Abstract ↑

  13. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001 Mar;56(3):M186-92. 

    Abstract ↑

  14. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72. 

    Abstract ↑

  15. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.

    Abstract ↑

  16. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res1999;19(4):117-27. 

    Abstract ↑

  17. Prat H, Roman O, Pino E. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia [Article in Spanish] Rev Med Chil 1999 Mar;127(3):286-94 

    Abstract ↑

  18. Mas R, Castano G, Illnait J, Fernandez L, Fernandez J, Aleman C, Pontigas V, Lescay M. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999 Apr;65(4):439-47. 

    Abstract ↑

  19. Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E, Castano G. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15(4):159-65. 

    Abstract ↑

  20. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33. 

    Abstract ↑

  21. Arruzazabala ML, Molina V, Mas R, Fernandez L, Carbajal D, Valdes S, Castano G Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 2002 Oct;29(10):891-7. 

    Abstract ↑

  22. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65. 

    Abstract ↑

  23. Mirkin A, Mas R, Martinto M, Boccanera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yanez M, Irico G, McCook B, Farre A. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001;21(1):31-41. 

    Abstract ↑

  24. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001 Mar;56(3):M186-92. 

    Abstract ↑

  25. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33. 

    Abstract ↑

  26. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72. 

    Abstract ↑

  27. Janikula M. Policosanol: a new treatment for cardiovascular disease?Altern Med Rev 2002 Jun;7(3):203-17. 

    Abstract ↑

  28. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65. 

    Abstract ↑

  29. Castano G, Mas R, Arruzazabala ML, Noa M, Illnait J, Fernandez JC, Molina V, Menendez A.Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res1999;19(4):105-16. 

    Abstract ↑

  30. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res1999;19(4):117-27. 

    Abstract ↑

  31. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65. 

    Abstract ↑

  32. Menendez R, Mas R, Amor AM, Gonzalez RM, Fernandez JC, Rodeiro I, Zayas M, Jimenez S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000 Sep;50(3):255-62. 

    Abstract ↑

  33. Arruzazabala ML, Molina V, Mas R, Fernandez L, Carbajal D, Valdes S, Castano G. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 2002 Oct;29(10):891-7. 

    Abstract ↑

  34. Castano G, Mas R, Arruzazabala ML, Noa M, Illnait J, Fernandez JC, Molina V, Menendez A.Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res1999;19(4):105-16. 

    Abstract ↑

  35. Ibid. 

    ↑

  36. Castano G, Mas Ferreiro R, Fernandez L, Gamez R, Illnait J, Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001 Feb;52(2):115-25 

    Abstract ↑

  37. Stusser R, Batista J, Padron R, Sosa F, Pereztol O. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther 1998 Sep;36(9):469-73. 

    Abstract ↑

  38. Aleman CL, Puig MN, Elias EC, Ortega CH, Guerra IR, Ferreiro RM, Brinis F.Carcinogenicity of policosanol in mice: an 18-month study. Food Chem Toxicol 1995 Jul;33(7):573-8. 

    Abstract ↑

  39. Aleman CL, Mas Ferreiro R, Noa Puig M, Rodeiro Guerra I, Hernandez Ortega C, Capote A. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 1994;14(5):239-49. 

    Abstract ↑

  40. Janikula M. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002 Jun;7(3):203-17. 

    Abstract ↑

  41. Rodriguez MD, Garcia H. Evaluation of peri- and post-natal toxicity of Policosanol in rats. Teratog Carcinog Mutagen 1998;18(1):1-7.Teratog Carcinog Mutagen 1994;14(3):107-13 

    Abstract ↑

  42. Rodriguez MD, Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen1994;14(3):107-13 

    Abstract ↑

  43. Rodriguez MD, Sanchez M, Garcia H.Multigeneration reproduction study of policosanol in rats. Toxicol Lett 1997 Feb 7;90(2-3):97-106.

    Abstract ↑

  44. Mesa AR, Mas R, Noa M, Hernandez C, Rodeiro I, Gamez R, Garcia M, Capote A, Aleman CL. Toxicity of policosanol in beagle dogs: one-year study. Toxicol Lett 1994 Aug;73(2):81-90. 

    Abstract ↑

  45. Aleman CL, Mas R, Hernandez C, Rodeiro I, Cerejido E, Noa M, Capote A, Menendez R, Amor A, Fraga V, et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett1994 Jan;70(1):77-87

    Abstract ↑

  46. Vella, C.A., Kravitz, L., & Janot, J.M. (2001). A review of the impact of exercise on cholesterol levels. IDEA Health & Fitness Source, 19, 10, p. 48. Retrieved March 26, 2002 from Expanded Academic ASAP. 

    ↑

  47. Lane, Jane, "Cholesterol Conundrum," Energy Times Feb. 1999 

    ↑

  48. www.cholestero

    ↑

  49. Blake, G.H. & Triplett, L.C. (1995). Management of Hypercholesterolemia. American Family Physician, 51, 5, p. 1157-1169. Retrieved March 26, 2002 from Expanded Academic ASAP.

    Abstract ↑

Articles of Interest from Smart Publications Health & Wellness Update